NCT06529523

Tislelizumab in People With Colorectal Cancer

PD-1 (Programmed Cell Death Protein 1) Blockade in Mismatch-repair Deficient Colorectal Cancer in Nigeria

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to find out whether tislelizumab is an effective treatment for people with colorectal cancer who are living in Nigeria. The researchers will also look at the safety of the study drug. All participants in this study will be treatment naïve (they have not yet received treatment for their cancer), and their cancer will be mismatch repair deficient (dMMR). dMMR cancer can happen when your cells are unable to repair mistakes made during the cell division process.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Patients will receive standard dose of tislelizumab 200mg IV flat dose q3weeks until disease progression, unacceptable toxicity, patient/physician decides to withdraw patient, death, or completion of 104 weeks treatment (35 administrations).

Timeline

• Start date: 2024-07-26
• Primary completion: 2028-07-01
• Completion: 2028-07-01
• First posted: 2024-07-31
• Last updated: 2025-10-07

Locations

3 sites across 2 countries: United States, Nigeria

Regulatory

• FDA-regulated drug study